DHR

Q4 2025

Date: 2026-01-28Rank: #3954Forward Promise: mixed

Danaher delivered a strong finish to 2025, beating expectations with Q4 sales of $6.8B (2.5% core growth) and adjusted EPS of $2.23 (+4% YoY). Full-year sales reached $24.6B with 2% core growth, while adjusted operating margins expanded to 28.2% and free cash flow hit $5.3B (145% conversion). The Bioprocessing segment led with high-single-digit growth, driven by robust consumables demand and a return to equipment revenue growth, while Diagnostics grew 2% aided by a respiratory beat. For 2026, management guided core revenue growth of 3%–6% and adjusted EPS of $8.35–$8.50, anticipating continued recovery in pharma and stable clinical markets, offset by persistent headwinds in academic and government end markets.

Bullishness Score

48.36

μ Mean

53.88

σ Uncertainty

1.84

Forward Promise

5.8

Management Tone

Management projected confidence in the durability of their end markets and the power of the Danaher Business System (DBS), particularly regarding margin expansion and free cash flow. However, they adopted a cautious, 'wait-and-see' posture in Q&A regarding the sustainability of the recent equipment recovery and the timing of a broader life sciences upturn, frequently emphasizing that one quarter does not make a trend.

Confidence: MEDIUM — While confident in long-term drivers (biologics, installed base) and DBS-fueled productivity, management hedged on near-term demand visibility, particularly in Life Sciences and Bioprocessing equipment, refusing to call the recent equipment growth a trend yet.

Strategic Signals

Management emphasized the 'reshoring' theme as a key long-term driver for Bioprocessing, suggesting the industry is in the 'early innings of a long-term investment cycle.' They noted that despite muted equipment investment recently, underlying demand remains strong, implying a future catch-up in capital spending that Danaher is uniquely positioned to capture.

Innovation remains a core pillar, with new product revenue growing approximately 25% year-over-year. Specific launches like Cytiva’s AcelRx X platform and Cepheid’s FDA-cleared GI panel highlight a strategy of leveraging the existing installed base to drive higher-margin consumables sales.

The company is actively prioritizing M&A, with CEO Rainer Blair noting the environment is 'more constructive' due to moderating interest rates and improving valuations. With a strong balance sheet (Debt/EBITDA < 2x) and robust cash generation, Danaher signaled readiness to deploy capital for strategic acquisitions that fit their end market criteria.

Operational discipline via the Danaher Business System (DBS) was highlighted as a critical offset to tariff and cost pressures. The $250 million in cost actions taken in 2025 (benefiting 2026 EPS by ~$0.30) demonstrates a willingness to restructure and right-size (e.g., Abcam) to protect margins during demand softness.

In Life Sciences, management is banking on a 'gradual improvement' driven by Pharma recovery post-MFN (Most Favored Nation) policy headwinds. They signaled that Pharma has grown for three consecutive quarters, providing a counterbalance to the muted Academic and Government sectors.

Key Metrics

Q4 Sales$6.8 Billion+2.5% Core

FY 2025 Sales$24.6 Billion+2.0% Core

Q4 Adj. EPS$2.23+4.0% YoY

FY 2025 Adj. EPS$7.80+4.5% YoY

Q4 Adj. Operating Margin28.3%-130 bps YoY

FY 2025 Free Cash Flow$5.3 Billion145% Conversion

Bioprocessing Core Growth (Q4)High Single DigitsN/A

Respiratory Revenue (FY 2026 Est)~$1.8 BillionN/A

Guidance

FY 2026 Core Revenue Growth: 3% to 6%

FY 2026 Adjusted Diluted EPS: $8.35 to $8.50

Q1 2026 Core Revenue Growth: Low Single Digits

Q1 2026 Adj. Operating Margin: Approximately 28.5%

FY 2026 Bioprocessing Growth: High Single Digits

FY 2026 Bioprocessing Equipment: Approximately Flat

Bottom Line

Price Target: N/A

Danaher remains a premier compounder in the life sciences and diagnostics space, underpinned by the Danaher Business System (DBS) and a high-quality recurring revenue model. While the near-term growth outlook is conservative (3-6%), the risk/reward is attractive. The company is successfully navigating a demand trough by leveraging productivity to expand margins and generate robust free cash flow ($5.3B in 2025). The investment case is bolstered by the 'reshoring' mega-trend in bioprocessing, which management believes is in its early innings, and the stabilization of the Pharma end market. The conservative guidance for equipment (flat) and life sciences (flat) creates a low bar for upside, particularly if the improved funding environment translates to orders. We view the current valuation as an opportunity to own a best-in-class franchise ahead of a likely multi-year capital expenditure cycle in bioprocessing.

Forward Promise

Overall: 5.8 · mixed

Cautiously optimistic management hedges on near-term equipment recovery.

Management confirmed the long-term thesis remains intact with strong end-market drivers, but they lack the visibility to aggressively call a near-term inflection, resulting in a conservative guide that sets the stage for potential beats.

Red Flags

Visibility into the Life Sciences recovery remains limited. Despite noting 'improvement,' management guided the segment for flat performance in 2026, citing muted academic/government demand and a lack of evidence that improved biotech funding is translating to orders yet. This creates a risk that the anticipated recovery pushes out yet again.

Bioprocessing equipment guidance was surprisingly conservative (flat for 2026) despite Q4 growth and easier comps. Management's reluctance to confirm a trend ('one quarter does not make a trend') suggests they lack confidence in the sustainability of the rebound, potentially signaling that customer capital expenditure budgets remain tight.

The guidance range of 3%–6% implies a significant reliance on back-half growth. The first quarter is guided for only 'low single-digit' core growth, and management noted that the low end of the EPS guide assumes only 3%–4% core growth for the year. This sets up a dependency on a second-half acceleration that may be vulnerable to macro shocks.

China remains a specific point of concern, with 'low single-digit decline' in Q4 and ongoing headwinds from volume-based procurement (VBP) policies. While VBP headwinds are expected to moderate, the region remains a drag on growth compared to the strength seen in other high-growth markets.

Macro Insights

Biotech Funding: Management noted an improved funding environment over the last 2-3 quarters, but has not yet seen this translate to a meaningful increase in the order book from emerging biotech companies.

Reshoring/Supply Chain: Discussions with pharma customers and CDMOs indicate that reshoring of bioprocessing capacity is advancing. Management believes the industry is in the 'early innings' of a long-term investment cycle to catch up on capacity needs.

China Healthcare Policy: Headwinds from Volume-Based Procurement (VBP) in China are expected to moderate as 2026 progresses, but they remain a drag on growth in the near term, particularly in Diagnostics.

Respiratory Illness Prevalence: High prevalence of circulating respiratory viruses (Flu, COVID, RSV) drove a Q4 beat. Management expects a 'normal' season in 2026, implying a stable endemic level of demand (~$1.8B).